June 28 (Reuters) - Sirtex Medical Ltd SRX.AX
* Staff to be reduced approximately 15% with restructuring provision (pre-tax) of $5.3 million in 2hfy17
* fy17 worldwide dose sales of approximately 12,590 were 5.5% higher compared with fy16
* Intangible clinical & research and development assets written off in non-cash (pre-tax) impairment charge of about $90 million in 2hfy17 Source text for Eikon: Further company coverage: SRX.AX